Perspective
Our work in Perspective
-
Addressing Value Defects from Wasteful Services through Health Technology Assessment
All parts of the health care delivery system—ranging from biotechnologies to provider-led health care services—should be held equally accountable for providing valuable services to patients.
Categorized in -
Eli Lilly Is Cutting Insulin Prices and Capping Copays at $35 – 5 Questions Answered
The drugmaker’s move responded to the growing competition that has shaken up the insulin market in recent years.
Categorized in -
Many Americans Wrongly Assume They Understand What Normal Blood Pressure Is – and That False Confidence Can Be Deadly
Nearly half of all Americans ages 20 and up have high blood pressure. Yet research shows that most people in the US don’t know the cutoff numbers for healthy blood.
Categorized in -
California’s Marijuana Market is Crumbling
The nation’s largest state should rescue its disintegrating cannabis market by raising the cost to illicit producers and sellers, not by violating federal law.
Categorized in -
A Simple Way to Reduce Overdose Deaths: Tell Doctors When Patients Die
If they think that the crisis is happening elsewhere, clinicians may underestimate the risk.
Categorized in -
American Life in Realtime: a Benchmark Registry of Health Data for Equitable Precision Health
Applying artificial intelligence and machine learning to person-generated health data allows unprecedented assessment of associations between everyday life and health outcomes.
Categorized in -
The FDA is the Right Agency to Regulate CBD Products, but It Needs Help
Undefined and unregulated, CBD will continue to pose unnecessary risks and never reach its potential as a legitimate health supplement.
Categorized in -
Small Cannabis Producers Have Bigger Problems than State Taxes and Regulation
Removing regulations and taxes on cannabis sales would take away resources that are needed to address legitimate public health concerns and won’t solve the supply-side problem.
Categorized in -
A New Approach to Cancer Bundled Payments in Medicare—The Enhancing Oncology Model
Schaeffer Nonresident Senior Fellow Bob Kocher discusses the elements of CMMI’s new Enhancing Oncology Model, explores its likelihood of success, and discusses its relative shortcomings in a new JAMA Health Forum Viewpoint.
Categorized in
